ALNY
NASDAQAlnylam Pharmaceuticals Inc.
Price$239.97+1.66 (+0.70%)
01:30 PM07:45 PM
News · 26 weeks66-40%
2026-03-012026-08-23
Mix1790d
- Other6(35%)
- SEC Filings4(24%)
- Insider3(18%)
- Earnings2(12%)
- Analyst2(12%)
Latest news
25 items- PRAlnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyretin (TTR) silencing with AMVUTTRA® (vutrisiran) and underscore the potential of zilebesiran as an innovative treatment approach for hypertension, the leading preventable risk factor for cardiovascular disease (CVD) worldwide. "We're e
- ANALYSTBMO Capital Markets initiated coverage on Alnylam Pharma with a new price targetBMO Capital Markets initiated coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $318.00
- ANALYSTAlnylam Pharma upgraded by Raymond James with a new price targetRaymond James upgraded Alnylam Pharma from Outperform to Strong Buy and set a new price target of $420.00
- SECSEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- SECAlnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- PRAlnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) – − Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared with 2025 at Revised Midpoint) – − Presented New Data from HELIOS-B at Heart Failure 2026 Demonstrating Vutrisiran's Consistent Clinical Benefit Across Patient Populations – − Advanced Pipeline with Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated Alzheimer's Disease; Results from Phase 1 Trial o
- PRAlnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial ResultsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via conference call on Thursday, July 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti
- PRAlnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) − − Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) − − Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) − − Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association
- PRKomodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence PlatformExpanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys
- PRAlnylam to Host Tenth "RNAi Roundtable" Webcast SeriesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of "RNAi Roundtable" webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company's pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company's website at investors.alnylam.com/events, and a replay will be posted on the Alnylam website approximately three hours after each event. The 2026 RNAi Roundtable schedule is as f
- PRAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics− Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam's RNAi platform and 20+ years of proprietary data with Inceptive's foundation models and AI expertise to catalyze progress beyond rational drug design – − Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cas
- INSIDERDirector Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERSEC Form 4 filed by Director Cravatt Benjamin4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cravatt Benjamin3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SECSEC Form 144 filed by Alnylam Pharmaceuticals Inc.144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
- PRAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumUSA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated
- SECAlnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- INSIDERDirector Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Reitan Colleen F was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Pyott David E I was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Kellogg Peter N was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Hamburg Margaret A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Brandicourt Olivier was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Ausiello Dennis A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
ALNY FAQ
7 questionsWhat does Alnylam Pharmaceuticals Inc. do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP)...Where does ALNY stock trade?
Alnylam Pharmaceuticals Inc. (ALNY) is listed on NASDAQ.What sector and industry is ALNY in?
Alnylam Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alnylam Pharmaceuticals Inc. go public?
Alnylam Pharmaceuticals Inc. (ALNY) completed its IPO in 2004.What are analysts saying about ALNY?
Alnylam Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform on 2026-08-19.What companies are similar to ALNY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ALNY side-by-side with any of them on Quantisnow.How can I track ALNY on Quantisnow?
Quantisnow aggregates Alnylam Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALNY to receive live email and push alerts on every new disclosure.